Hungria Vania, Garnica Marcia, Crusoé Edvan de Queiroz, Magalhaes Filho Roberto Jose Pessoa de, Martinez Gracia, Bittencourt Rosane, Farias Danielle Leão Cordeiro de, Braga Walter Moises, Neto Jorge Vaz Pinto, Ribeiro Glaciano Nogueira, Maiolino Angelo
Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano, São Paulo, SP, Brazil.
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Complexo Hospitalar de Niterói (CHN), Niterói, RJ, Brazil.
Hematol Transfus Cell Ther. 2020 Jul-Sep;42(3):200-205. doi: 10.1016/j.htct.2020.05.001. Epub 2020 May 13.
Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
自全球面临新冠疫情以来，癌症患者受到了特别关注；鉴于他们的免疫抑制状态，感染更具侵袭性的新冠病毒以及死亡风险增加，同时也担忧癌症治疗的可及性和医疗质量。新冠疫情影响了感染人数、相关死亡率以及癌症患者的治疗。多发性骨髓瘤患者是一个特殊群体，在疫情期间有几个重要方面需要考虑。本质上，他们在治疗期间处于不同程度的免疫抑制状态。他们中的大多数是老年人，并且所有人都需要长期治疗，与医疗保健系统有长期接触，治疗过程中可能还包括干细胞移植。一组多发性骨髓瘤和传染病专家讨论了骨髓瘤患者在新冠疫情背景下的证据情况以及证据不足的地方，同时也阐述了对新冠疫情下一阶段的预期。
